[go: up one dir, main page]

CN103193712B - A kind of preparation method of N-BETA-Alanyl-L-histidine - Google Patents

A kind of preparation method of N-BETA-Alanyl-L-histidine Download PDF

Info

Publication number
CN103193712B
CN103193712B CN201210002213.9A CN201210002213A CN103193712B CN 103193712 B CN103193712 B CN 103193712B CN 201210002213 A CN201210002213 A CN 201210002213A CN 103193712 B CN103193712 B CN 103193712B
Authority
CN
China
Prior art keywords
product
alanyl
beta
histidine
carnosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210002213.9A
Other languages
Chinese (zh)
Other versions
CN103193712A (en
Inventor
赵新
齐巧艳
计国桢
陆建刚
邢健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUZHOU FUSHILAI PHARMACEUTICAL Co Ltd
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Changshu Fushilai Medicine & Chemical Co ltd
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changshu Fushilai Medicine & Chemical Co ltd, Shanghai Institute of Organic Chemistry of CAS filed Critical Changshu Fushilai Medicine & Chemical Co ltd
Priority to CN201210002213.9A priority Critical patent/CN103193712B/en
Publication of CN103193712A publication Critical patent/CN103193712A/en
Application granted granted Critical
Publication of CN103193712B publication Critical patent/CN103193712B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a kind of preparation method of N-BETA-Alanyl-L-histidine, comprise by phthalyl-N-BETA-Alanyl-L-histidine and organic amine in a solvent reacting by heating slough protecting group, after separating out product, filter, solvent wash, drying, obtain N-BETA-Alanyl-L-histidine product; Or through concentrated, crystallization, filtration and drying, obtain without hydrazine N-BETA-Alanyl-L-histidine product.Its advantage is that method is easy, and cost is low, workable, does not have toxic compounds hydrazine in gained carnosine product, the quality of product is fully ensured and embodies the security of product to health.

Description

一种L-肌肽的制备方法A kind of preparation method of L-carnosine

技术领域 technical field

本发明属于有机化合物制备技术领域,具体涉及一种L-肌肽的制备方法。The invention belongs to the technical field of organic compound preparation, and in particular relates to a preparation method of L-carnosine.

背景技术 Background technique

L-肌肽(英文名:L-Carnosine,CAS号:305-84-0)由俄国科学家Gulewitsh与Amiradzibi于1900年首次在牛肉中检测到,在哺乳动物的大脑、肌肉和其他有神经分布的组织中广泛存在,在动物体内其浓度大约为1-20mmol.L-1,尤其是在鸡胸脯肉中的含量特别高。在生物体内,它由肌肽合成酶利用β-丙氨酸和L-组氨酸合成,化学名为β-丙氨酰-L-组氨酸,其化学结构式如下:L-carnosine (English name: L-Carnosine, CAS No.: 305-84-0) was first detected in beef by Russian scientists Gulewitsh and Amiradzibi in 1900. It is found in mammalian brain, muscle and other tissues with nerve distribution. It exists widely in animals, and its concentration in animals is about 1-20mmol.L -1 , especially in chicken breast meat. In organisms, it is synthesized by carnosine synthase using β-alanine and L-histidine. The chemical name is β-alanyl-L-histidine, and its chemical structure is as follows:

L-肌肽能参与和调节人体的各种生理活动,具有极好的天然抗氧化、清除自由基、与过渡金属螯合、神经保护、促进伤口愈合和抗衰老等作用,以及对高血压、心脏病、老年性白内障、溃疡的愈合等都有治疗效果,所以在医药、保健、卫生等领域具有广泛的应用前景。L-carnosine can participate in and regulate various physiological activities of the human body. It has excellent natural anti-oxidation, scavenging free radicals, chelating with transition metals, neuroprotection, promoting wound healing and anti-aging, and has effects on hypertension, heart disease, etc. Disease, senile cataract, ulcer healing, etc. have therapeutic effects, so it has broad application prospects in the fields of medicine, health care, and hygiene.

目前,L-肌肽的化学合成方法主要是首先通过用邻苯二甲酸酐保护β-丙氨酸中的氨基,反应得到邻苯二甲酰β-丙氨酸,再与L-组氨酸缩合得到中间体邻苯二甲酰-L-肌肽,该中间体用水合肼经过肼解反应脱去保护基,再经脱色、浓缩、结晶、过滤和干燥,得到产品L-肌肽。典型的文献报道如公开号为CN101117334A(合成L-肌肽的新方法)和CN101284862A(L-肌肽的合成方法)的专利,以及非专利文献(L-肌肽的合成研究,陈建辉,吴志刚,建清,氨基酸与生物资源,2008,30,50-52)等等。At present, the chemical synthesis method of L-carnosine is mainly to first protect the amino group in β-alanine with phthalic anhydride, react to obtain phthalyl β-alanine, and then condense with L-histidine The intermediate phthaloyl-L-carnosine is obtained, and the protective group of the intermediate is removed through hydrazinolysis reaction with hydrazine hydrate, and then the product L-carnosine is obtained through decolorization, concentration, crystallization, filtration and drying. Typical bibliographical reports are the patents of CN101117334A (new method for synthesizing L-carnosine) and CN101284862A (synthetic method for L-carnosine) as publication number, and non-patent literature (synthetic research of L-carnosine, Chen Jianhui, Wu Zhigang, Jian Qing, Amino Acids and Biological Resources, 2008, 30, 50-52) and so on.

上述方法具有原料易得,工艺路线较短,总收率较高等优点,但是,由于在生产过程中使用了水合肼,导致在L-肌肽产品中有一定的肼残留(20ppm左右)。The above-mentioned method has the advantages that raw materials are easy to get, the processing route is shorter, and the total yield is higher. However, due to the use of hydrazine hydrate in the production process, certain hydrazine residues (about 20 ppm) are arranged in the L-carnosine product.

如业界所周知,肼属于高毒类化学品,对人体健康有较大危害,进入人体的方式可以通过吸入、食入和经皮肤吸收等途径,使人出现头晕、恶心和使中枢神经系统兴奋等中毒症状。此外,肼还被认为是一种可疑致癌物。因此,如何有效地降低乃至完全清除L-肌肽产品中的肼残留,始终是业界长期关注并渴望解决的技术问题。然而,迄今为止,在已公开的中外专利和非专利文献中均没有相应的技术启示来制备无肼肌肽,为此,本申请人经过多次探索,找到了解决问题的方法,在保持主流制备技术的基础上,通过利用其他非肼的脱保护试剂来脱除邻苯二甲酰基,从源头上清除肼了的来源,通过对采用该技术得到的成品L-肌肽产品的检测,证明该方法完全行之有效,彻底解决了目前主流的肼解法制备L-肌肽的产品中肼残留难题,下面将要介绍的技术方案便是在这种背景下产生的。As is well known in the industry, hydrazine is a highly toxic chemical that is harmful to human health. It can enter the human body through inhalation, ingestion, and skin absorption, causing dizziness, nausea, and excitement to the central nervous system. and other symptoms of poisoning. In addition, hydrazine is considered a suspected carcinogen. Therefore, how to effectively reduce or even completely remove the residue of hydrazine in L-carnosine products has always been a technical problem that the industry has been paying attention to for a long time and is eager to solve. However, so far, there is no corresponding technical suggestion in the published Chinese and foreign patents and non-patent literature to prepare hydrazine-free carnosine. For this reason, the applicant has found a solution to the problem after many explorations. On the basis of technology, by using other non-hydrazine deprotection reagents to remove phthaloyl group, remove the source of hydrazine from the source, and prove this method by detecting the finished L-carnosine product obtained by using this technology It is completely effective and completely solves the problem of hydrazine residue in the product of L-carnosine prepared by the current mainstream hydrazinolysis method. The technical solution to be introduced below is produced under this background.

发明内容 Contents of the invention

本发明要解决的问题是提供一种完全没有肼残留的无肼L-肌肽的制备方法,籍以保障产品品质和体现L-肌肽产品对人体健康的安全性。The problem to be solved in the present invention is to provide a method for preparing hydrazine-free L-carnosine without hydrazine residues at all, so as to ensure product quality and reflect the safety of L-carnosine products on human health.

本发明提供如下的一种L-肌肽的制备方法:将邻苯二甲酰-L-肌肽与有机胺在溶剂中加热反应脱去保护基反应得到L-肌肽。该方法还可以进一步包括:反应后得到的L-肌肽产物析出后经过滤、有机溶剂洗涤、干燥,得到L-肌肽产品。或者该方法还可以进一步包括:反应后得到的L-肌肽产物经浓缩、结晶、过滤和干燥,得到L-肌肽产品。The invention provides a preparation method of L-carnosine as follows: phthalyl-L-carnosine and organic amine are heated and reacted in a solvent to remove the protective group and react to obtain L-carnosine. The method may further include: the L-carnosine product obtained after the reaction is precipitated, filtered, washed with an organic solvent, and dried to obtain the L-carnosine product. Or the method may further include: the L-carnosine product obtained after the reaction is concentrated, crystallized, filtered and dried to obtain the L-carnosine product.

本发明的上述制备方法得到的L-肌肽是无肼L-肌肽。The L-carnosine obtained by the above preparation method of the present invention is hydrazine-free L-carnosine.

本发明所述的邻苯二甲酰-L-肌肽具有如下结构式:Phthaloyl-L-carnosine of the present invention has following structural formula:

所述的有机胺推荐为1至4个碳原子的直链或支链有机胺,例如甲胺、乙胺、丙胺、丁胺等一级胺(伯胺)。The organic amines are recommended to be linear or branched organic amines with 1 to 4 carbon atoms, such as primary amines (primary amines) such as methylamine, ethylamine, propylamine, and butylamine.

所述的有机胺用量为等当量或过量,例如邻苯二甲酰-L-肌肽与有机胺的摩尔比为1∶(1~4)。The amount of the organic amine is equivalent or excessive, for example, the molar ratio of phthaloyl-L-carnosine to the organic amine is 1: (1-4).

所述的脱去保护基的反应时间推荐为1~3小时。The recommended reaction time for removing the protecting group is 1-3 hours.

所述的溶剂为水或有机溶剂中的至少一种,所述有机溶剂选自C1~C6的醇、C2~C6的酮、乙腈、四氢呋喃(THF)或二氧六环等中的至少一种或者它们的混合溶剂,例如甲醇、乙醇、丙醇、丁醇、丙酮、异丙醇、乙腈、四氢呋喃或二氧六环等中的至少一种。The solvent is at least one of water or an organic solvent selected from C 1 -C 6 alcohols, C 2 -C 6 ketones, acetonitrile, tetrahydrofuran (THF) or dioxane, etc. At least one of or their mixed solvents, such as at least one of methanol, ethanol, propanol, butanol, acetone, isopropanol, acetonitrile, tetrahydrofuran or dioxane, etc.

所述的加热反应脱去保护基的反应温度为30℃至回流,所述的回流温度是指的溶剂回流温度。进一步推荐反应温度为30~80℃。The reaction temperature of the heating reaction to remove the protecting group is from 30° C. to reflux, and the reflux temperature refers to the solvent reflux temperature. Further recommended reaction temperature is 30-80°C.

所述的洗涤用溶剂为C1~C6的醇、C2~C6的酮、C2~C6的醚、C2~C6的酯或C1~C6的卤代烷中的至少一种,例如甲醇、乙醇、丙醇、丙酮、异丙醇、乙醚、乙酸乙酯或二氯甲烷等中的至少一种。The washing solvent is at least one of C 1 -C 6 alcohol, C 2 -C 6 ketone, C 2 -C 6 ether, C 2 -C 6 ester or C 1 -C 6 haloalkane species, such as at least one of methanol, ethanol, propanol, acetone, isopropanol, ether, ethyl acetate, or dichloromethane.

所述的浓缩、结晶推荐是经减压或常压蒸馏除去反应用的溶剂后,加入结晶用的溶剂加热回流至析出产物。所述的结晶用溶剂为C1~C6的醇,例如甲醇、乙醇或异丙醇等。The recommended concentration and crystallization is to remove the reaction solvent by distillation under reduced pressure or normal pressure, then add the solvent for crystallization and heat to reflux until the product is precipitated. The solvent for crystallization is a C 1 -C 6 alcohol, such as methanol, ethanol or isopropanol.

本发明由于不使用水合肼来脱除L-肌肽的保护基,从而从源头上避免了肼的引入,完全消除了产品中肼残留的可能性,使得L-肌肽产品的品质得以充分保证并且体现出产品对人体健康的安全性。Since the present invention does not use hydrazine hydrate to remove the protecting group of L-carnosine, the introduction of hydrazine is avoided from the source, and the possibility of hydrazine residue in the product is completely eliminated, so that the quality of L-carnosine products can be fully guaranteed and reflected The safety of products to human health.

具体实施方式 Detailed ways

本发明的内容结合以下实施例作更进一步的说明,但本发明的内容不仅限于实施例中所涉及的内容:Content of the present invention is further described in conjunction with the following examples, but content of the present invention is not limited to the content involved in the examples:

实施例1:Example 1:

向250mL反应瓶中,加入邻苯二甲酰-L-肌肽7.12克(2mmol)和一甲胺水溶液(30%,质量比)80mL,此混合体系在80℃搅拌2小时,停止反应,除去溶剂,加入无水乙醇200mL,搅拌并加热回流,析出白色粉末状固体,过滤,20mL乙醚洗涤,干燥,得到肌肽产品3.87克,产率:88%。产品中未检出肼。Add 7.12 grams (2 mmol) of phthaloyl-L-carnosine and 80 mL of monomethylamine aqueous solution (30%, mass ratio) to a 250 mL reaction flask, and stir the mixed system at 80 ° C for 2 hours to stop the reaction and remove the solvent , adding 200 mL of absolute ethanol, stirring and heating to reflux, a white powdery solid was precipitated, filtered, washed with 20 mL of ether, and dried to obtain 3.87 g of carnosine product, yield: 88%. Hydrazine was not detected in the product.

实施例2:Example 2:

向500mL反应瓶中,加入邻苯二甲酰-L-肌肽14.2克(4mmol),甲胺乙醇溶液(27-30%,质量比)14mL和无水乙醇350mL,加热回流1小时。热过滤,2×80mL无水乙醇洗,2×80mL乙醚洗,干燥,得肌肽产品8.02克,产率89%。产品中未检出肼。Add 14.2 g (4 mmol) of phthaloyl-L-carnosine, 14 mL of methylamine ethanol solution (27-30%, mass ratio) and 350 mL of absolute ethanol into a 500 mL reaction flask, and heat to reflux for 1 hour. Filtrate hot, wash with 2×80 mL of absolute ethanol, wash with 2×80 mL of ether, and dry to obtain 8.02 g of carnosine product with a yield of 89%. Hydrazine was not detected in the product.

实施例3:Example 3:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),异丙醇30mL和甲胺水溶液(30%,质量比)4mL,加热回流1.5h,热过滤,2×80mL无水乙醇洗,2×80mL乙醚洗,干燥,得肌肽产品1.68克,产率74%。Add 3.56 g (1 mmol) of phthaloyl-L-carnosine, 30 mL of isopropanol and 4 mL of methylamine aqueous solution (30%, mass ratio) to a 100 mL reaction flask, heat to reflux for 1.5 h, and heat filter, 2×80 mL Wash with absolute ethanol, wash with 2×80 mL ether, and dry to obtain 1.68 g of carnosine product, with a yield of 74%.

实施例4:Example 4:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),异丙醇30mL和甲胺乙醇溶液4mL(27-30%,质量比),加热回流1h,趁热过滤,2×60mL无水乙醇洗,2×40mL乙醚洗,干燥,得肌肽产品1.8克,产率80%。Add 3.56 g (1 mmol) of phthaloyl-L-carnosine, 30 mL of isopropanol and 4 mL of methylamine-ethanol solution (27-30%, mass ratio) into a 100 mL reaction flask, heat to reflux for 1 hour, and filter while hot. Wash with 2×60 mL of absolute ethanol, 2×40 mL of ether, and dry to obtain 1.8 g of carnosine product with a yield of 80%.

实施例5:Example 5:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),THF 30mL和甲胺水溶液(30%,质量比)4mL,加热回流2小时,除去溶剂,所得固体加入乙醇100mL回流,过滤,2×60mL无水甲醇洗,干燥,得肌肽产品1.51克,产率69%。In a 100mL reaction flask, add 3.56 grams (1 mmol) of phthaloyl-L-carnosine, 30 mL of THF and 4 mL of methylamine aqueous solution (30%, mass ratio), heat to reflux for 2 hours, remove the solvent, and add 100 mL of ethanol to the obtained solid Reflux, filter, wash with 2×60 mL of anhydrous methanol, and dry to obtain 1.51 g of carnosine product with a yield of 69%.

实施例6:Embodiment 6:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),四氢呋喃30mL和甲胺乙醇溶液4mL(27-30%,质量比),回流3小时,趁热过滤,2×60mL无水乙醇洗,2×30mL乙酸乙酯洗,干燥,得肌肽产品1.60克,产率71%。Add 3.56 g (1 mmol) of phthaloyl-L-carnosine, 30 mL of tetrahydrofuran and 4 mL of methylamine ethanol solution (27-30%, mass ratio) into a 100 mL reaction flask, reflux for 3 hours, filter while hot, 2× Wash with 60 mL of absolute ethanol, 2×30 mL of ethyl acetate, and dry to obtain 1.60 g of carnosine product with a yield of 71%.

实施例7:Embodiment 7:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),二氧六环30mL和甲胺水溶液(30%,质量比)4mL,加热回流2小时,趁热过滤,2×30mL二氯甲烷洗,干燥,得肌肽产品2.04克,产率90%。In a 100mL reaction flask, add 3.56 grams (1 mmol) of phthaloyl-L-carnosine, 30 mL of dioxane and 4 mL of methylamine aqueous solution (30%, mass ratio), heat to reflux for 2 hours, and filter while hot, 2 ×30mL dichloromethane washed, dried to obtain carnosine product 2.04g, yield 90%.

实施例8:Embodiment 8:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),二氧六环30mL和甲胺乙醇溶液5mL(27-30%,质量比),加热回流2.5h,除去溶剂,加入无水乙醇100mL,搅拌并加热回流,析出白色粉末固体,过滤,20mL乙醇洗涤,干燥,得到肌肽产品2.2克,产率97%。Add 3.56 g (1 mmol) of phthaloyl-L-carnosine, 30 mL of dioxane and 5 mL of methylamine ethanol solution (27-30%, mass ratio) into a 100 mL reaction flask, heat to reflux for 2.5 h, and remove the solvent , adding absolute ethanol 100mL, stirring and heating to reflux, a white powder solid was precipitated, filtered, washed with 20mL of ethanol, and dried to obtain 2.2 grams of carnosine product with a yield of 97%.

实施例9:Embodiment 9:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),乙醇30ml和正丙胺3.8mL,加热回流2小时,过滤,20mL异丙醇洗涤,干燥,得到肌肽产2.04克,产率90%。Add 3.56 grams (1 mmol) of phthaloyl-L-carnosine, 30 ml of ethanol and 3.8 mL of n-propylamine to a 100 mL reaction flask, heat to reflux for 2 hours, filter, wash with 20 mL of isopropanol, and dry to obtain 2.04 grams of carnosine. Yield 90%.

实施例10:Example 10:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),乙醇30mL和正丁胺3.7mL,加热回流2小时,过滤,20mL无水乙醇洗涤,干燥,得到肌肽产品2.14克,产率95%。Add 3.56 grams (1 mmol) of phthaloyl-L-carnosine, 30 mL of ethanol and 3.7 mL of n-butylamine to a 100 mL reaction flask, heat to reflux for 2 hours, filter, wash with 20 mL of absolute ethanol, and dry to obtain 2.14 grams of carnosine product , 95% yield.

实施例11:Example 11:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),水30ml和乙胺水溶液(65-70%,质量比)4mL,加热回流1小时,除去溶剂,加30mL乙醇回流,冷却,过滤,20mL乙醇洗涤,干燥,得到肌肽产品1.37克,产率61%。Add 3.56 g (1 mmol) of phthaloyl-L-carnosine, 30 ml of water and 4 mL of ethylamine aqueous solution (65-70%, mass ratio) to a 100 mL reaction flask, heat to reflux for 1 hour, remove the solvent, and add 30 mL of ethanol Reflux, cool, filter, wash with 20 mL of ethanol, and dry to obtain 1.37 g of carnosine product with a yield of 61%.

实施例12:Example 12:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),丙酮30mL和甲胺水溶液(30%,质量比)4mL,加热回流反应2小时,除去溶剂,加30mL乙醇回流,冷却,过滤,20mL乙醇洗涤,干燥,得到肌肽产品1.54克,产率68%。Add 3.56 g (1 mmol) of phthaloyl-L-carnosine, 30 mL of acetone and 4 mL of methylamine aqueous solution (30%, mass ratio) into a 100 mL reaction flask, heat to reflux for 2 hours, remove the solvent, add 30 mL of ethanol to reflux , cooled, filtered, washed with 20 mL of ethanol, and dried to obtain 1.54 grams of carnosine product, with a yield of 68%.

实施例13:Example 13:

向100mL反应瓶中,加入邻苯二甲酰-L-肌肽3.56克(1mmol),乙醇30mL和异丙胺3.0mL,加热回流反应2.5小时,除去溶剂,加30mL乙醇回流,冷却,过滤,20mL乙醇洗涤,干燥,得到肌肽产品:1.4克,产率62%。Add 3.56 g (1 mmol) of phthaloyl-L-carnosine, 30 mL of ethanol and 3.0 mL of isopropylamine to a 100 mL reaction flask, heat to reflux for 2.5 hours, remove the solvent, add 30 mL of ethanol to reflux, cool, filter, and 20 mL of ethanol Wash and dry to obtain carnosine product: 1.4 g, yield 62%.

Claims (8)

1. a preparation method for N-BETA-Alanyl-L-histidine, is characterized in that in a solvent with 30 DEG C under reflux temperature, and the organic primary amine of phthalyl-N-BETA-Alanyl-L-histidine and 1 to 2 carbon atom obtains N-BETA-Alanyl-L-histidine after reacting and sloughing protecting group in 1 ~ 3 hour; The mol ratio of described phenyl-diformyl-N-BETA-Alanyl-L-histidine and the organic primary amine of 1 to 2 carbon atom is 1:(1 ~ 4).
2. preparation method according to claim 1, is characterized in that described reaction to be sloughed after protecting group through separating out product, filtration, organic solvent washing and drying, obtaining N-BETA-Alanyl-L-histidine product.
3. preparation method according to claim 1, is characterized in that described reaction to be sloughed after protecting group through concentrated, crystallization, filtration and drying, obtains N-BETA-Alanyl-L-histidine product.
4. the preparation method according to claim 1,2 or 3, is characterized in that described N-BETA-Alanyl-L-histidine product is without hydrazine N-BETA-Alanyl-L-histidine product.
5. preparation method according to claim 1, is characterized in that described solvent is selected from water, C 1~ C 6alcohol, C 2~ C 6ketone, acetonitrile, tetrahydrofuran (THF), dioxane or their mixed solvent.
6. preparation method according to claim 2, is characterized in that described washing organic solvent is C 1~ C 6alcohol, C 2~ C 6ketone, C 2~ C 6ether, C 2~ C 6ester or C 1~ C 6haloalkane at least one.
7. preparation method according to claim 3, is characterized in that described crystallization solvent is C 1~ C 6alcohol.
8. preparation method according to claim 1, is characterized in that described temperature of reaction is 30 ~ 80 DEG C.
CN201210002213.9A 2012-01-05 2012-01-05 A kind of preparation method of N-BETA-Alanyl-L-histidine Active CN103193712B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210002213.9A CN103193712B (en) 2012-01-05 2012-01-05 A kind of preparation method of N-BETA-Alanyl-L-histidine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210002213.9A CN103193712B (en) 2012-01-05 2012-01-05 A kind of preparation method of N-BETA-Alanyl-L-histidine

Publications (2)

Publication Number Publication Date
CN103193712A CN103193712A (en) 2013-07-10
CN103193712B true CN103193712B (en) 2015-09-16

Family

ID=48716548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210002213.9A Active CN103193712B (en) 2012-01-05 2012-01-05 A kind of preparation method of N-BETA-Alanyl-L-histidine

Country Status (1)

Country Link
CN (1) CN103193712B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108047138A (en) * 2017-12-25 2018-05-18 湖北泓肽生物科技有限公司 Preparation method without hydrazine N-BETA-Alanyl-L-histidine
CN110419618A (en) * 2019-07-25 2019-11-08 李猷 A kind of animal albumen powder and preparation method thereof rich in carnosine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070050319A (en) * 2005-11-10 2007-05-15 주식회사 엔지켐 Method for preparing L-carnosine and its derivatives
CN101117334A (en) * 2006-08-04 2008-02-06 浙江医药股份有限公司新昌制药厂 Novel method for synthesizing L-carnosine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070050319A (en) * 2005-11-10 2007-05-15 주식회사 엔지켐 Method for preparing L-carnosine and its derivatives
CN101117334A (en) * 2006-08-04 2008-02-06 浙江医药股份有限公司新昌制药厂 Novel method for synthesizing L-carnosine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
John Debenham,等."Recent Advances in N-Protection for Amino Sugar Synthesis".《Liebigs Ann.lRecuel》.1997,791-802,尤其是第792页方案1. *

Also Published As

Publication number Publication date
CN103193712A (en) 2013-07-10

Similar Documents

Publication Publication Date Title
EP3818057A1 (en) Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile
HUE027545T2 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
CN106588788B (en) One-pot two-step method for synthesizing 1,2,3-triazoles
CN103193712B (en) A kind of preparation method of N-BETA-Alanyl-L-histidine
CN102260288A (en) Synthesis method of 3-amino-propyl aminoethyl thiophosphate trihydrate
Qiao et al. Six novel complexes based on 5-Acetoxy-1-(6-chloro-pyridin-2-yl)-1H-pyrazole-3-carboxylic acid methyl ester derivatives: Syntheses, crystal structures, and anti-cancer activity
CN102267983B (en) Sym-triazine derivative compounds containing sym-tetrazine rings and preparation method thereof
CN102464699A (en) A kind of preparation method of sodium carbenate
JP6761564B2 (en) L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of L-proline compound
US8946474B2 (en) Polymorphic form of a calcimimetic compound
CN106117104B (en) A kind of preparation method of vildagliptin
WO2019142205A1 (en) An improved process for preparation of quaternary pyridinium salts
CN106167459B (en) A method of synthesis alkenyl thiocyanates derivative
JP2018104312A (en) Imidazopyrroloquinoline salt and method for producing the same, and pharmaceutical, cosmetic and food
CN101671306B (en) A kind of preparation method of L-carnosine
CN104447308B (en) The synthetic method of methyl hydroxybenzoate
CN103435586B (en) Containing the polyamine derivative and its preparation method and application of flavones structure
WO2018171371A2 (en) Preparation method for bis-dicarboxylic acid diammine platinum (ii) derivative
CN105732407B (en) Synthesis method of acetyl levocarnitine inner salt
CN112175032B (en) Rapid synthesis of 5-substituted-4-thio-2',3'-O-di-tert-butyldisilyldeoxynucleoside compounds
CN108586429A (en) The purifying process for purification of r-lipoic acid cholinester halide
CN102206185A (en) Process for refining bendazac lysine and analogs thereof
CN107778307B (en) Preparation method of central alpha 2 adrenoreceptor agonist
CN109422723B (en) Crystal form of intestinal 2B type sodium phosphate cotransporter inhibitor and preparation method thereof
CN109384791B (en) Crystal form of imidazo isoindole derivative free alkali and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 200032 Shanghai city Xuhui District Fenglin Road No. 354

Co-patentee after: SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD.

Patentee after: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences

Address before: 200032 Shanghai city Xuhui District Fenglin Road No. 354

Co-patentee before: Changshu Fushilai Medicine Chemical Co., Ltd.

Patentee before: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences